Effect of sacubitril-valsartan on cardiac function in hemodialysis patients

Effect of sacubitril-valsartan on cardiac function in hemodialysis patients - Sacubitril-valsartan in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044773

Enrollment

Registered

2021-07-06

Start date

2020-11-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

50 mg of sacubitril-valsartan twice daily at least 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: LVEF<50% or N-terminal proBNP >5000 ng/L

Exclusion criteria

Exclusion criteria: sys. BP <120 mmHg

Design outcomes

Primary

Measure	Time frame
Changes in left ventricular ejection fraction and N-terminal proBNP level(pre, 4, 8 and 12 weeks).	—

Countries

Japan

Contacts

Public ContactShoichiro Daimon

Daimon Clinic for Internal Medicine, Nephrology and Dialysis Department of Nephrology

dai-clinic@m2.spacelan.ne.jp+81762940077

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026